Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BAP5191 in Healthy Adults
NCT05848453Phase 1Completed
- Sponsor
- Bacoba AG
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of leflunomide in cutaneous leishmaniasis (CL) (3 cohorts), sponsored by Bacoba AG. Primary endpoints: General safety (number, frequency, severity, seriousness and duration of adverse events), Blood pressure from baseline and 5 more. Started Mar 2023; status: completed.
02
Drugs
leflunomide
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT05848453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05848453.